18F-FET-PET引导的大部全切除改善WHO III/IV级胶质瘤总生存
该回顾性研究纳入30例原发或复发WHO III/IV级胶质瘤患者,术前行FET-PET并计算生物肿瘤体积(BTV)切除程度。20例达到PET GTR(残留BTV<1 cm3),其中位OS为19.3个月,显著优于残留FET摄取者的13.7个月(p=0.007;HR 0.3;95%CI 0.12-0.76),多因素分析仍为独立预后因素(HR 0.19,95%CI 0.06-0.62,p=0.006)。
要点
- FET-PET可定义MRI增强之外的BTV,指导胶质瘤切除范围。
- PET GTR(残留BTV<1 cm3)与更优OS独立相关。
- 多模态影像引导手术可能改善原发和复发胶质瘤预后。
核心结论
- PET GTR改善WHO III或IV级胶质瘤患者的总生存。
- 包含FET-PET的多模态影像手术规划可能改善肿瘤学结局。
研究设计与样本
- 回顾性分析30例原发和复发WHO III或IV级胶质瘤患者的影像与生存数据。
- 患者切除术前接受FET-PET,术后MRI与术前FET-PET叠加半自动分割计算PET GTR。
- 生存分析采用Kaplan-Meier法和log-rank检验,并行多因素分析。
主要发现
- 30例中20例达到PET GTR。
- PET GTR组中位OS为19.3个月,残留FET摄取组为13.7个月(p=0.007;HR 0.3;95%CI 0.12-0.76)。
- 多因素分析显示PET GTR为独立预后因素(HR 0.19,95%CI 0.06-0.62,p=0.006)。
- 年龄、IDH突变、MGMT启动子状态和辅助治疗在两组间分布均衡。
关键数值与推荐
- PET GTR定义为残留BTV<1 cm3。
- FET-PET所显示的BTV在体积和位置上常与MRI增强肿瘤体积不同。
临床怎么用
- 对原发和复发WHO III/IV级胶质瘤,可考虑术前FET-PET评估BTV以指导切除范围。
- 追求残留BTV<1 cm3的PET GTR可能作为改善OS的手术目标。
局限性
- 回顾性设计,样本量30例。
- 单中心数据,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET using radiolabeled amino acid [18F]-fluoro-ethyl-L-tyrosine (FET-PET) is a well-established imaging modality for glioma diagnostics. The biological tumor volume (BTV) as depicted by FET-PET often differs in volume and location from tumor volume of contrast enhancement (CE) in MRI. Our aim was to investigate whether a gross total resection of BTVs defined as < 1 cm3 of residual BTV (PET GTR) correlates with better oncological outcome. METHODS: We retrospectively analyzed imaging and survival data from patients with primary and recurrent WHO grade III or IV gliomas who underwent FET-PET before surgical resection. Tumor overlap between FET-PET and CE was evaluated. Completeness of FET-PET resection (PET GTR) was calculated after superimposition and semi-automated segmentation of pre-operative FET-PET and postoperative MRI imaging. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. RESULTS: From 30 included patients, PET GTR was achieved in 20 patients. Patients with PET GTR showed improved median OS with 19.3 compared to 13.7 months for patients with residual FET uptake (p = 0.007; HR 0.3; 95% CI 0.12-0.76). This finding remained as independent prognostic factor after performing multivariate analysis (HR 0.19, 95% CI 0.06-0.62, p = 0.006). Other survival influencing factors such as age, IDH-mutation, MGMT promotor status, and adjuvant treatment modalities were equally distributed between both groups. CONCLUSION: Our results suggest that PET GTR improves the OS in patients with WHO grade III or IV gliomas. A multimodal imaging approach including FET-PET for surgical planning in newly diagnosed and recurrent tumors may improve the oncological outcome in glioma patients.
引用
- Ort J, Hamou HA, Kernbach JM, et al. 18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. J Neurooncol. 2021. PMID: 34599479. doi:10.1007/s11060-021-03844-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。